Review of Clinical Trials for Huntington's Disease Treatments
Author Information
Author(s): Alharthi Mohammed S.
Primary Institution: Taif University
Hypothesis
What are the pharmacological treatments being tested in phase III and IV clinical trials for Huntington's disease?
Conclusion
Current medications aim to manage Huntington's disease symptoms, potentially improving outcomes and reducing disease progression risks.
Supporting Evidence
- Eight clinical trials met the inclusion criteria for the study.
- Medications tested include minocycline, valbenazine, deutetrabenazine, tominersen, pridopidine, and memantine.
- Valbenazine showed significant improvement in chorea symptoms compared to placebo.
- Pridopidine demonstrated potential benefits in motor functions.
- Memantine was well-tolerated and showed potential cognitive benefits.
Takeaway
This study looks at different medicines being tested to help people with Huntington's disease feel better and live better lives.
Methodology
The review analyzed publicly available phase III and IV clinical trials registered at ClinicalTrials.gov.
Potential Biases
Potential bias due to reliance on a single source of clinical trial information.
Limitations
The study relied solely on ClinicalTrials.gov, which may introduce bias and limit the comprehensiveness of the findings.
Participant Demographics
The trials included adult patients aged 18-64 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website